[{"address1": "4 Kingsbury Avenue", "city": "Watertown", "state": "MA", "zip": "02472", "country": "United States", "phone": "617 607 0800", "fax": "617 607 0530", "website": "https://www.enanta.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.", "fullTimeEmployees": 131, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jay R. Luly Ph.D.", "age": 68, "title": "President, CEO & Director", "yearBorn": 1956, "fiscalYear": 2024, "totalPay": 1231428, "exercisedValue": 0, "unexercisedValue": 67815}, {"maxAge": 1, "name": "Mr. Paul J. Mellett Jr.", "age": 69, "title": "Chief Financial & Administrative Officer", "yearBorn": 1955, "fiscalYear": 2024, "totalPay": 671700, "exercisedValue": 0, "unexercisedValue": 21320}, {"maxAge": 1, "name": "Dr. Yat Sun Or Ph.D.", "age": 72, "title": "Chief Scientific Officer", "yearBorn": 1952, "fiscalYear": 2024, "totalPay": 740108, "exercisedValue": 0, "unexercisedValue": 22091}, {"maxAge": 1, "name": "Mr. Matthew P. Kowalsky J.D.", "age": 51, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 575652, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Scott T. Rottinghaus M.D.", "age": 50, "title": "Chief Medical Office", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 776138, "exercisedValue": 43483, "unexercisedValue": 14728}, {"maxAge": 1, "name": "Ms. Jennifer  Viera", "title": "Executive Director of Investor Relations & Corporate Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nathaniel S. Gardiner J.D.", "age": 70, "title": "Consultant", "yearBorn": 1954, "fiscalYear": 2024, "totalPay": 672675, "exercisedValue": 49136, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tara Lynn Kieffer Ph.D.", "age": 46, "title": "Chief Product Strategy Officer", "yearBorn": 1978, "fiscalYear": 2024, "totalPay": 496852, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brendan  Luu", "age": 49, "title": "Chief Business Officer", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 622856, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 4, "compensationRisk": 6, "shareHolderRightsRisk": 8, "overallRisk": 6, "governanceEpochDate": 1754006400, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 7.58, "open": 7.42, "dayLow": 7.1, "dayHigh": 7.65, "regularMarketPreviousClose": 7.58, "regularMarketOpen": 7.42, "regularMarketDayLow": 7.1, "regularMarketDayHigh": 7.65, "payoutRatio": 0.0, "beta": 0.847, "forwardPE": -1.4751037, "volume": 182763, "regularMarketVolume": 182763, "averageVolume": 165648, "averageVolume10days": 203040, "averageDailyVolume10Day": 203040, "bid": 7.08, "ask": 7.24, "bidSize": 2, "askSize": 2, "marketCap": 151987632, "fiftyTwoWeekLow": 4.09, "fiftyTwoWeekHigh": 13.5, "priceToSalesTrailing12Months": 2.35775, "fiftyDayAverage": 7.1776, "twoHundredDayAverage": 7.144025, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 174754496, "profitMargins": -1.49566, "floatShares": 14358649, "sharesOutstanding": 21376600, "sharesShort": 2463124, "sharesShortPriorMonth": 2498915, "sharesShortPreviousMonthDate": 1749772800, "dateShortInterest": 1752537600, "sharesPercentSharesOut": 0.115200005, "heldPercentInsiders": 0.06565, "heldPercentInstitutions": 0.87248003, "shortRatio": 16.41, "shortPercentOfFloat": 0.1224, "impliedSharesOutstanding": 21376600, "bookValue": 4.376, "priceToBook": 1.6247716, "lastFiscalYearEnd": 1727654400, "nextFiscalYearEnd": 1759190400, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -96415000, "trailingEps": -4.53, "forwardEps": -4.82, "enterpriseToRevenue": 2.711, "enterpriseToEbitda": -1.766, "52WeekChange": -0.4466926, "SandP52WeekChange": 0.20277917, "quoteType": "EQUITY", "currentPrice": 7.11, "targetHighPrice": 24.0, "targetLowPrice": 7.0, "targetMeanPrice": 18.2, "targetMedianPrice": 20.0, "recommendationMean": 1.8, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 193375008, "totalCashPerShare": 9.046, "ebitda": -98944000, "totalDebt": 216142000, "quickRatio": 5.093, "currentRatio": 5.286, "totalRevenue": 64463000, "debtToEquity": 231.074, "revenuePerShare": 3.035, "returnOnAssets": -0.17329, "returnOnEquity": -0.74265, "grossProfits": 64463000, "freeCashflow": -72374624, "operatingCashflow": -55464000, "revenueGrowth": -0.125, "grossMargins": 1.0, "ebitdaMargins": -1.5349001, "operatingMargins": -1.6432401, "financialCurrency": "USD", "symbol": "ENTA", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": -6.20053, "regularMarketPrice": 7.11, "shortName": "Enanta Pharmaceuticals, Inc.", "longName": "Enanta Pharmaceuticals, Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1363872600000, "postMarketChangePercent": 0.0, "postMarketPrice": 7.11, "postMarketChange": 0.0, "regularMarketChange": -0.47, "regularMarketDayRange": "7.1 - 7.65", "corporateActions": [], "postMarketTime": 1754078559, "regularMarketTime": 1754078402, "exchange": "NMS", "messageBoardId": "finmb_345286", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "CLOSED", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 165648, "fiftyTwoWeekLowChange": 3.02, "fiftyTwoWeekLowChangePercent": 0.7383863, "fiftyTwoWeekRange": "4.09 - 13.5", "fiftyTwoWeekHighChange": -6.39, "fiftyTwoWeekHighChangePercent": -0.47333333, "fiftyTwoWeekChangePercent": -44.66926, "earningsTimestamp": 1747080060, "earningsTimestampStart": 1754942400, "earningsTimestampEnd": 1754942400, "earningsCallTimestampStart": 1715027400, "earningsCallTimestampEnd": 1715027400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -4.53, "epsForward": -4.82, "epsCurrentYear": -4.22, "priceEpsCurrentYear": -1.6848342, "fiftyDayAverageChange": -0.06759977, "fiftyDayAverageChangePercent": -0.009418159, "twoHundredDayAverageChange": -0.034024715, "twoHundredDayAverageChangePercent": -0.0047626817, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.8 - Buy", "cryptoTradeable": false, "displayName": "Enanta Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-08-02"}]